Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
17 search results for:

SABCS 2020 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 09-12-2020 | SABCS 2020 | Conference coverage | Article

    Updated monarchE data show continued abemaciclib benefit

    Osborne continued: “With these caveats in mind, this is still an extremely important trial that could be practice changing in this very high-risk patient population […] if the results continue to be positive and show improved overall survival with longer follow-up.” medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2020 Springer Healthcare Ltd, part of the Springer Nature Group SABCS 2020: 8–11 December

    Author:
    Shreeya Nanda
    Published in:
    SABCS 2020: 8–11 December
  2. 22-12-2020 | SABCS 2020 | Conference coverage | Article

    ​​​​​​​TNBC patients benefit from pembrolizumab in combination with various chemotherapies

    Overall, Rugo concluded that these findings “further support a role for the addition of pembrolizumab to standard chemotherapy for the first-line treatment of metastatic TNBC.” medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2020 Springer Healthcare Ltd, part of the Springer Nature Group SABCS 2020: 8–11 December

    Author:
    Hannah Kitt
    Published in:
    SABCS 2020: 8–11 December
  3. play
    17-12-2020 | SABCS 2020 | Conference coverage | Video

    Updated findings on low-risk MINDACT participants reported

    SABCS 2020 video: Laura van 't Veer discusses the latest data from the MINDACT trial of adjuvant chemotherapy de-escalation in hormone

  4. 17-12-2020 | SABCS 2020 | Conference coverage | Article

    Palbociclib use does not extend IDFS for high-risk breast cancer patients

    “To date the results of PENELOPE-B do not support the addition of 1 year palbociclib to endocrine therapy,” she said, but emphasized that long-term follow-up is awaited for adjuvant CDK4/6 inhibitor, as well as translational research and subgroup analyses. medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2020 Springer Healthcare Ltd, part of the Springer Nature Group SABCS 2020; 8–11 December

    Author:
    Lynda Williams
    Published in:
    SABCS 2020; 8–11 December
  5. 16-12-2020 | SABCS 2020 | Conference coverage | Article

    Integrated tool may individualize prognosis prediction in early breast cancer

    Sparano et al say their findings show that patient-specific meta-analysis methods “may be used in conjunction with randomized clinical trials to develop tools that facilitate more effective application of precision medicine in cancer therapy.” medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2020 Springer Healthcare Ltd, part of the Springer Nature Group SABCS 2020: 8–11 December J Clin Oncol 2020; doi:10.1200/JCO.20.03007

    Author:
    Laura Cowen
    Published in:
    SABCS 2020: 8–11 December J Clin Oncol 2020; doi:10.1200/JCO.20.03007
  6. 15-12-2020 | SABCS 2020 | Conference coverage | Article

    Use of addictive medications not uncommon after mastectomy

    “Rather, patients should be vigilant about taking these medications only when necessary, and they should work closely with the prescribing provider to attempt to minimize risk of dependence,” he concluded. medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2020 Springer Healthcare Ltd, part of the Springer Nature Group SABCS 2020: 8–11 December

    Author:
    Shreeya Nanda
    Published in:
    SABCS 2020: 8–11 December
  7. 15-12-2020 | SABCS 2020 | Conference coverage | Article

    Postmenopausal HR-positive early BC patients may ‘safely forgo’ adjuvant chemotherapy

    He concluded that “additional follow-up is ongoing, and future analyses will also include [quality of life] and other outcomes.” medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2020 Springer Healthcare Ltd, part of the Springer Nature Group SABCS 2020: 8–11 December

    Author:
    Lynda Williams
    Published in:
    SABCS 2020: 8–11 December
  8. 15-12-2020 | SABCS 2020 | Conference coverage | Article

    CONTESSA: Tesetaxel plus capecitabine boosts metastatic breast cancer PFS

    The corresponding rates of treatment-related deaths were 1.8% and 0.9%. medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2020 Springer Healthcare Ltd, part of the Springer Nature Group SABCS 2020: 8–11 December

    Author:
    Shreeya Nanda
    Published in:
    SABCS 2020: 8–11 December
  9. 14-12-2020 | SABCS 2020 | Conference coverage | Article

    ​​​​​​​IBIS-II update shows no difference in anastrozole, tamoxifen efficacy in DCIS

    Sestak therefore concluded that “an improved understanding of adverse event profiles will help patients with [HR]-positive [DCIS] to make an informed decision regarding their treatment.” medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2020 Springer Healthcare Ltd, part of the Springer Nature Group SABCS 2020: 8–11 December

    Author:
    Hannah Kitt
    Published in:
    SABCS 2020: 8–11 December
  10. 10-12-2020 | SABCS 2020 | Conference coverage | Article

    Breast cancer radiotherapy side effects often under-recognized

    “Our study identifies some concerning patterns that need to be evaluated in future research, along with opportunities for intervention to improve the quality and equity of cancer care delivery,” she concluded. medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2020 Springer Healthcare Ltd, part of the Springer Nature Group SABCS 2020: 8–11 December

    Author:
    Shreeya Nanda
    Published in:
    SABCS 2020: 8–11 December
  11. play
    14-12-2020 | SABCS 2020 | Conference coverage | Video

    Adjuvant chemotherapy omission feasible for certain postmenopausal breast cancer patients

    SABCS 2020 video: Kevin Kalinsky presents the SWOG S1007 RxPONDER trial of adjuvant chemotherapy in early-stage, HR-positive breast cancer patients

  12. play
    19-12-2020 | SABCS 2020 | Conference coverage | Video

    Adjuvant CDK4/6 inhibition in early-stage HR-positive breast cancer

    Ruth O'Regan comments on the monarchE trial of abemaciclib and the PENELOPE-B and PALLAS trials of palbociclib investigating CDK4/6 inhibitor therapy in the adjuvant, hormone receptor-positive, early-stage breast cancer setting (6:35).

  13. play
    11-12-2020 | SABCS 2020 | Conference coverage | Video

    Comparable outcomes, different toxicities with anastrozole, tamoxifen in DCIS

    SABCS 2020 video: Ivana Sestak puts the IBIS-II trial results in the context of the NSABP B-35 study, both of which pitted anastrozole vs tamoxifen

  14. play
    11-12-2020 | SABCS 2020 | Conference coverage | Video

    Meta-analysis provides reassurance regarding pregnancy after breast cancer

    SABCS 2020 video: Matteo Lambertini discusses their meta-analysis evaluating the reproductive and disease outcomes of pregnancy in breast cancer

  15. play
    10-12-2020 | SABCS 2020 | Conference coverage | Video

    Biomarker data point to wide use of sacituzumab govitecan in advanced TNBC

    SABCS 2020 news: Sara Hurvitz outlines the biomarker data from the phase 3 ASCENT clinical trial of sacituzumab govitecan in metastatic TNBC.

  16. play
    14-12-2020 | SABCS 2020 | Conference coverage | Video

    Entinostat addition fails to improve aromatase inhibitor-resistant breast cancer outcomes

    Roisin Connolly discusses the next steps following the negative results of the phase 3 ECOG-ACRIN E2112 trial of the HDAC inhibitor entinostat in combination with endocrine therapy in aromatase inhibitor-resistant patients with advanced breast cancer.

  17. 28-08-2020 | SABCS 2020 | Conference coverage | Channel

    San Antonio Breast Cancer Symposium 2020

    News and expert video interviews from the San Antonio Breast Cancer Symposium (SABCS 2020) including coverage of the PENELOPE-B, RISAS, and CONTESSA trials.

  • 1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.